News

A clinician and researcher at the University of California, San Francisco highlighted how agentic AI frameworks are being integrated into real-world multiple sclerosis research to streamline big data analysis and accelerate clinically meaningful discovery. [Watch Time: 5 minutes]

Full data from the FENhance studies of fenebrutinib will be presented at the 2026 American Academy of Neurology Annual Meeting and submitted for regulatory review along with FENtrepid data in multiple sclerosis.

Neuro-oncology experts examined how cumulative neurotoxicity from cytotoxic and targeted therapies can obscure paraneoplastic neurologic syndromes, and how treatment timing and modification decisions influence neurologic outcomes. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, also spoke about what he personally is most looking forward to at this year's meeting.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is diagnostic workup for multiple system atrophy!

Global site reactivation for the MAGNITUDE-2 trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy is underway, with enrollment completion expected in the second half of 2026.

Neurology News Network for the week ending February 28, 2026. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

Anjail Sharrief, MD, Director of Stroke Prevention for the Institute of Stroke and Cerebrovascular Disease at UTHealth Houston, reflects on Black History Month, structural drivers of stroke inequities, and building systems that advance equitable brain health.

Neuro-oncology experts discussed how to differentiate classic PNS from immune-related neurologic adverse events, including the impact of prior immunotherapy exposure and the challenge of balancing neurologic stabilization with ongoing cancer treatment. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lauren Sansing, MD, MS, FAHA, FANA. [LISTEN TIME: 27 minutes]

Praxis files FDA NDAs for ulixacaltamide and relutrigine, highlighting phase 3 tremor gains and major seizure cuts in rare DEEs.

Phase 3 data showed efgartigimod improved ocular myasthenia symptoms, paving way for FDA filing and potential first targeted option for patients.

Grip strength offers neurologists a responsive, objective measure that captures treatment effects and real-world fluctuations—complementing disability scales and helping to guide decision-making in clinical practice.

MARINA trial shows del-desiran siRNA reaches muscle, lowers toxic DMPK RNA in DM1, with early functional gains.

In early-morning shift workers with shift work disorder, solriamfetol significantly improved objective and subjective measures of sleepiness compared with placebo in a trial published in the New England Journal of Medicine.

EryDex failed to significantly improve neurologic outcomes compared with placebo in pediatric patients with ataxia-telangiectasia in the phase 3 NEAT trial.

Neuro-oncology experts outlined screening strategies, antibody testing, and patient factors that help distinguish paraneoplastic neurologic syndromes from treatment toxicity and immune-related events. [WATCH TIME: 6 minutes]

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

Kyle Marden, MD, sports neurologist at Northwestern Medicine, discussed the growing role of sports neurologists and new data supporting the feasibility of quantitative pupillometry as part of a multimodal approach to concussion diagnosis and recovery tracking.

Early ALS trial showed that microbiome gut-brain therapy PLL001 is safe, paving way for 6-month phase 2 study testing efficacy and gut repair.

In this Q&A, migraine expert Deena Kuruvilla, MD, FAAN, provided clinical context on the phase 4 COMPEL trial testing onabotulinumtoxinA as a preventive treatment of chronic migraine in diverse racial groups.

Two-year phase 3 data show Elevidys gene therapy slows Duchenne decline in boys, improving NSAA and walk tests with manageable safety.

The senior research investigator at the New York Stem Cell Foundation answered questions about the research efforts needed to advance iPSC human models toward clinical relevance for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Off-label rimegepant was associated with patient-reported acute migraine improvement and no new safety signals in a small retrospective review of adolescent patients.